Compare abrdn Physical Palladium Shares ETF (PALL) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
abrdn Physical Palladium Shares ETF vs GeneDx Holdings Corp — how do they compare? abrdn Physical Palladium Shares ETF trades at $24.47, while GeneDx Holdings Corp trades at $86.53 (market cap $2.58B). The key difference: GeneDx Holdings Corp is trading nearer its 52-week high, abrdn Physical Palladium Shares ETF nearer its low. Which is the better fit depends on your goals.
| PALL | WGS | |
|---|---|---|
Sector | Commodities - Metals/Agriculture | Technology |
52-Week High | $37.18 | $167.51 |
52-Week Low | $20.97 | $34.51 |
Market Cap | — | $2.58B |
Enterprise Value | — | $2.61B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PALL, the Aberdeen Physical Palladium Shares ETF, trades at $24.43, down 3.48% over 24 hours. Technical indicators are bearish, with moving averages signaling sell pressure, while oscillators are neutral. Recent news highlights palladium's underperformance relative to other precious metals, with some analysts viewing current price weakness as a potential buying opportunity due to supply risks and industrial demand.
The outlook for PALL hinges on palladium's supply-demand dynamics and broader commodity trends. Investment opportunities exist if palladium prices rebound from support levels, but risks include continued commodity volatility and macroeconomic pressures affecting industrial demand.
WGS trades at $85.87, down 0.14% today, with a bullish technical signal from moving averages and support at $84. The company reported Q2 2026 revenue of $114.4M, beating estimates, and returned to adjusted profitability early. However, net income remains negative at -$106M for 2026, with high valuation multiples like EV/EBITDA of 161.17. Recent news highlights partnerships and product launches, such as the NPC GenomeComplete initiative with Beren Therapeutics.
Outlook is mixed: strong analyst buy consensus (90.9%) and institutional interest support upside, but profitability challenges and a class action lawsuit pose risks. Revenue growth and operational improvements are key catalysts, yet high debt-to-asset ratios and negative margins require monitoring for sustained recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About abrdn Physical Palladium Shares ETF
PALL is a physically-backed ETF that tracks the spot price of palladium. It holds physical bullion in secure vaults, offering a liquid way to invest in this precious metal primarily used in automotive catalytic converters and electronics.
Read more on PALL →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
